Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
4 trials since 2013, 3 ongoing, by the sponsor of the products; see every authorized trial
Phase 3 trial to evaluate the long-term safety and efficacy of navenibart in participants with hereditary angioedema –…Sep 26, 2025 · Ongoing · Navenibart
Phase 3, multicenter, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of…Mar 19, 2025 · Ongoing · Navenibart (STAR-0215)
A phase 2 long-term open-label trial to assess the safety and efficacy of repeat dosing of STAR-0215 in adult patients…Jan 17, 2024 · Ongoing · Navenibart
A phase 1b/2 single and multiple dose study to assess the safety, tolerability, clinical activity, pharmacokinetics,…Dec 13, 2022 · Closed · STAR-0215
Orphan designations (FDA)
One designation since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
NavenibartTreatment of hereditary angioedema · Sep 26, 2024
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.